BATON ROUGE, La., April 23, 2025 (GLOBE NEWSWIRE) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2025.
Three-Month Periods Ended March 31, 2025 and 2024
- Net service revenue increased $23.4 million to $594.8 million compared to $571.4 million in 2024.
- Net income attributable to Amedisys, Inc. of $61.0 million, which is inclusive of merger-related expenses totaling $16.8 million ($16.6 million, net of tax) and a $48.1 million gain on an equity method investment ($35.6 million, net of tax), compared to net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-related expenses totaling $20.7 million ($19.8 million, net of tax) in 2024.
- Net income attributable to Amedisys, Inc. per diluted share of $1.84 compared to $0.44 in 2024.
Adjusted Quarterly Results*
- Adjusted EBITDA of $68.8 million compared to $59.9 million in 2024.
- Adjusted net income attributable to Amedisys, Inc. of $41.6 million compared to $33.9 million in 2024.
- Adjusted net income attributable to Amedisys, Inc. per diluted share of $1.25 compared to $1.03 in 2024.
* See pages 7 – 8 for the definition and reconciliations of non-GAAP financial measures to GAAP measures.
The supplemental slides provided in connection with the first quarter 2025 earnings release can be found on the Investor Relations page of our website. In light of the pending merger of the Company with UnitedHealth Group Incorporated, Amedisys will not conduct a quarterly earnings call to discuss the first quarter results.
Non-GAAP Financial Measures
This press release includes reconciliations of the most comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”) to non-GAAP financial measures. The non-GAAP financial measures as defined under SEC rules are as follows: (1) adjusted EBITDA, defined as net income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items; (2) adjusted net income attributable to Amedisys, Inc., defined as net income attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items; and (3) adjusted net income attributable to Amedisys, Inc. per diluted share, defined as net income attributable to Amedisys, Inc. common stockholders per diluted share calculated in accordance with GAAP excluding certain items. Certain items include merger-related expenses, unusual or non-recurring expenses and certain non-operational items. Management believes that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, are useful gauges of our current performance and are also included in internal management reporting. These non-GAAP financial measures should be considered in addition to, and not more meaningful than or as an alternative to, the GAAP financial measures presented in this earnings release and the company’s financial statements. Non-GAAP measures as presented herein may not be comparable to similarly titled measures reported by other companies since not all companies calculate these non-GAAP measures consistently.
Additional Information
Amedisys, Inc. (the “Company”) is a leading healthcare services company, delivering personalized home health, hospice and high acuity care services in the home. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based recovery and rehabilitation after an operation or injury, care focused on empowering our patients to manage a chronic disease, hospice care at the end of life or in-patient hospital, palliative and skilled nursing facility (“SNF”) care in their homes. More than 3,300 hospitals and 114,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 19,000 employees in 519 care centers within 38 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 499,000 patients every year. For more information about the Company, please visit: www.amedisys.com.
We use our website as a channel of distribution for important company information. Important information, including press releases, investor presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.
Forward-Looking Statements
When included in this press release, words like “believes,” “belief,” “expects,” “strategy,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “will,” “could,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to, the following: disruption from the proposed merger with UnitedHealth Group with patient, payor, provider, referral source, supplier or management and employee relationships; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement with UnitedHealth Group or the inability to complete the proposed transaction on the anticipated terms or by the end of the waiver period under the merger agreement; the risk that necessary regulatory approvals for the proposed merger with UnitedHealth Group are delayed, are not obtained or are obtained subject to conditions that are not anticipated; the failure of the conditions to the proposed merger to be satisfied; the costs related to the proposed transaction; the diversion of management time on merger-related issues; the risk that termination fees may be payable by the Company in the event that the merger agreement is terminated under certain circumstances; reputational risk related to the proposed merger; the risk of litigation or regulatory action related to the proposed merger, including among other things, the action by the Department of Justice to block the merger; changes in Medicare and other medical payment levels; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; changes in the episodic versus non-episodic mix of our payors, the case mix of our patients and payment methodologies; staffing shortages driven by the competitive labor market; our ability to attract and retain qualified personnel; competition in the healthcare industry; our ability to maintain or establish new patient referral sources; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; changes in estimates and judgments associated with critical accounting policies; our ability to consistently provide high-quality care; our ability to keep our patients and employees safe; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural or man-made disasters, climate change or acts of terrorism, widespread protests or civil unrest; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; our ability to integrate, manage and keep our information systems secure; the impact of inflation; the impact of new or increased tariffs; uncertainty around, and disruption from, new and emerging technologies, including the adoption and utilization of artificial intelligence (“AI”) and generative AI and changes in laws or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking, and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.
| Contact: | Investor Contact: Amedisys, Inc. Nick Muscato Chief Strategy Officer (615) 928- 5452 IR@amedisys.com | Media Contact: Amedisys, Inc. Kendra Kimmons Vice President, Marketing & Communications (225) 299-3720 kendra.kimmons@amedisys.com |
| AMEDISYS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED INCOME STATEMENTS (Amounts in thousands, except per share data) | |||||||
| For the Three-Month Periods Ended March 31, | |||||||
| 2025 | 2024 | ||||||
| Net service revenue | $ | 594,781 | $ | 571,414 | |||
| Operating expenses: | |||||||
| Cost of service, inclusive of depreciation | 334,050 | 321,537 | |||||
| General and administrative expenses: | |||||||
| Salaries and benefits | 131,968 | 127,946 | |||||
| Non-cash compensation | 6,223 | 7,433 | |||||
| Merger-related expenses | 16,769 | 20,667 | |||||
| Depreciation and amortization | 4,447 | 4,271 | |||||
| Other | 57,965 | 57,941 | |||||
| Total operating expenses | 551,422 | 539,795 | |||||
| Operating income | 43,359 | 31,619 | |||||
| Other income (expense): | |||||||
| Interest income | 2,873 | 1,727 | |||||
| Interest expense | (6,422 | ) | (8,119 | ) | |||
| Equity in earnings from equity method investments | 1,794 | 910 | |||||
| Gain on equity method investment | 48,093 | — | |||||
| Miscellaneous, net | 1,508 | 1,090 | |||||
| Total other income (expense), net | 47,846 | (4,392 | ) | ||||
| Income before income taxes | 91,205 | 27,227 | |||||
| Income tax expense | (29,384 | ) | (12,633 | ) | |||
| Net income | 61,821 | 14,594 | |||||
| Net income attributable to noncontrolling interests | (809 | ) | (194 | ) | |||
| Net income attributable to Amedisys, Inc. | $ | 61,012 | $ | 14,400 | |||
| Basic earnings per common share: | |||||||
| Net income attributable to Amedisys, Inc. common stockholders | $ | 1.86 | $ | 0.44 | |||
| Weighted average shares outstanding | 32,793 | 32,670 | |||||
| Diluted earnings per common share: | |||||||
| Net income attributable to Amedisys, Inc. common stockholders | $ | 1.84 | $ | 0.44 | |||
| Weighted average shares outstanding | 33,218 | 32,979 | |||||
| AMEDISYS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands, except share data) | |||||||
| March 31, 2025 | December 31, 2024 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 284,881 | $ | 303,242 | |||
| Patient accounts receivable | 319,639 | 296,075 | |||||
| Prepaid expenses | 17,410 | 13,072 | |||||
| Other current assets | 12,034 | 19,694 | |||||
| Total current assets | 633,964 | 632,083 | |||||
| Property and equipment, net of accumulated depreciation of $103,758 and $100,890 | 40,186 | 42,108 | |||||
| Operating lease right of use assets | 80,905 | 81,500 | |||||
| Goodwill | 1,213,888 | 1,213,888 | |||||
| Intangible assets, net of accumulated amortization of $19,949 and $18,787 | 80,199 | 81,155 | |||||
| Other assets | 135,432 | 87,980 | |||||
| Total assets | $ | 2,184,574 | $ | 2,138,714 | |||
| LIABILITIES AND EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 28,705 | $ | 39,956 | |||
| Payroll and employee benefits | 131,722 | 151,995 | |||||
| Accrued expenses | 162,180 | 152,564 | |||||
| Termination fee paid by UnitedHealth Group | 106,000 | 106,000 | |||||
| Current portion of long-term obligations | 37,579 | 37,968 | |||||
| Current portion of operating lease liabilities | 25,845 | 25,909 | |||||
| Total current liabilities | 492,031 | 514,392 | |||||
| Long-term obligations, less current portion | 332,947 | 339,313 | |||||
| Operating lease liabilities, less current portion | 55,642 | 56,111 | |||||
| Deferred income tax liabilities | 58,032 | 48,051 | |||||
| Other long-term obligations | 848 | 882 | |||||
| Total liabilities | 939,500 | 958,749 | |||||
| Equity: | |||||||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding | — | — | |||||
| Common stock, $0.001 par value, 60,000,000 shares authorized; 38,381,255 and 38,307,521 shares issued; 32,818,871 and 32,776,148 shares outstanding | 38 | 38 | |||||
| Additional paid-in capital | 825,138 | 818,201 | |||||
| Treasury stock, at cost, 5,562,384 and 5,531,373 shares of common stock | (477,718 | ) | (474,854 | ) | |||
| Retained earnings | 852,168 | 791,156 | |||||
| Total Amedisys, Inc. stockholders’ equity | 1,199,626 | 1,134,541 | |||||
| Noncontrolling interests | 45,448 | 45,424 | |||||
| Total equity | 1,245,074 | 1,179,965 | |||||
| Total liabilities and equity | $ | 2,184,574 | $ | 2,138,714 | |||
| AMEDISYS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS AND DAYS REVENUE OUTSTANDING (Amounts in thousands, except statistical information) | |||||||
| For the Three-Month Periods Ended March 31, | |||||||
| 2025 | 2024 | ||||||
| Cash Flows from Operating Activities: | |||||||
| Net income | $ | 61,821 | $ | 14,594 | |||
| Adjustments to reconcile net income to net cash used in operating activities: | |||||||
| Depreciation and amortization (inclusive of depreciation included in cost of service) | 6,787 | 6,138 | |||||
| Non-cash compensation | 6,844 | 7,886 | |||||
| Amortization and impairment of operating lease right of use assets | 8,645 | 8,566 | |||||
| (Gain) loss on disposal of property and equipment | (34 | ) | 4 | ||||
| Gain on equity method investment | (48,093 | ) | — | ||||
| Deferred income taxes | 9,981 | 2,594 | |||||
| Equity in earnings from equity method investments | (1,794 | ) | (910 | ) | |||
| Amortization of deferred debt issuance costs | 248 | 248 | |||||
| Return on equity method investments | 2,320 | 170 | |||||
| Changes in operating assets and liabilities: | |||||||
| Patient accounts receivable | (23,564 | ) | (46,806 | ) | |||
| Other current assets | 3,480 | (1,696 | ) | ||||
| Operating lease right of use assets | (1,186 | ) | (1,042 | ) | |||
| Other assets | 88 | 155 | |||||
| Accounts payable | (10,913 | ) | 8,652 | ||||
| Accrued expenses | (10,658 | ) | 3,029 | ||||
| Other long-term obligations | (34 | ) | (591 | ) | |||
| Operating lease liabilities | (7,625 | ) | (7,532 | ) | |||
| Net cash used in operating activities | (3,687 | ) | (6,541 | ) | |||
| Cash Flows from Investing Activities: | |||||||
| Proceeds from the sale of deferred compensation plan assets | 27 | 21 | |||||
| Proceeds from the sale of property and equipment | 15 | — | |||||
| Purchases of property and equipment | (1,215 | ) | (2,670 | ) | |||
| Investments in technology assets | (201 | ) | (223 | ) | |||
| Investment in equity method investee | — | (196 | ) | ||||
| Net cash used in investing activities | (1,374 | ) | (3,068 | ) | |||
| Cash Flows from Financing Activities: | |||||||
| Proceeds from the issuance of stock upon exercise of stock options | 93 | — | |||||
| Shares withheld to pay taxes on non-cash compensation | (2,864 | ) | (617 | ) | |||
| Noncontrolling interest contributions | — | 1,764 | |||||
| Noncontrolling interest distributions | (785 | ) | (756 | ) | |||
| Principal payments of long-term obligations | (9,744 | ) | (8,941 | ) | |||
| Net cash used in financing activities | (13,300 | ) | (8,550 | ) | |||
| Net decrease in cash, cash equivalents and restricted cash | (18,361 | ) | (18,159 | ) | |||
| Cash, cash equivalents and restricted cash at beginning of period | 303,242 | 138,863 | |||||
| Cash, cash equivalents and restricted cash at end of period | $ | 284,881 | $ | 120,704 | |||
| Supplemental Disclosures of Cash Flow Information: | |||||||
| Cash paid for interest | $ | 6,177 | $ | 8,188 | |||
| Cash paid for income taxes, net of refunds received | $ | 907 | $ | 828 | |||
| Cash paid for operating lease liabilities | $ | 8,811 | $ | 8,574 | |||
| Cash paid for finance lease liabilities | $ | 4,121 | $ | 2,236 | |||
| Supplemental Disclosures of Non-Cash Activity: | |||||||
| Right of use assets obtained in exchange for operating lease liabilities | $ | 7,006 | $ | 7,173 | |||
| Right of use assets obtained in exchange for finance lease liabilities | $ | 3,158 | $ | 4,326 | |||
| Reductions to right of use assets resulting from reductions to operating lease liabilities | $ | 75 | $ | 168 | |||
| Reductions to right of use assets resulting from reductions to finance lease liabilities | $ | 415 | $ | 496 | |||
| Days revenue outstanding (1) | 45.7 | 54.1 | |||||
(1) Our calculation of days revenue outstanding at March 31, 2025 and 2024 is derived by dividing our ending patient accounts receivable by our average daily patient revenue for the three-month periods ended March 31, 2025 and 2024, respectively.
| AMEDISYS, INC. AND SUBSIDIARIES RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP MEASURES (Amounts in thousands, except per share data) | ||||||
| Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“Adjusted EBITDA”) Reconciliation: | ||||||
| For the Three-Month Periods Ended March 31, | ||||||
| 2025 | 2024 | |||||
| Net income attributable to Amedisys, Inc. | $ | 61,012 | $ | 14,400 | ||
| Add: | ||||||
| Income tax expense | 29,384 | 12,633 | ||||
| Interest expense, net | 3,549 | 6,392 | ||||
| Depreciation and amortization | 6,787 | 6,138 | ||||
| Certain items(1) | (31,903 | ) | 20,296 | |||
| Adjusted EBITDA(2)(5) | $ | 68,829 | $ | 59,859 | ||
Adjusted Net Income Attributable to Amedisys, Inc Reconciliation:
| For the Three-Month Periods Ended March 31, | ||||||
| 2025 | 2024 | |||||
| Net income attributable to Amedisys, Inc. | $ | 61,012 | $ | 14,400 | ||
| Add: | ||||||
| Certain items(1) | (19,430 | ) | 19,548 | |||
| Adjusted net income attributable to Amedisys, Inc.(3)(5) | $ | 41,582 | $ | 33,948 | ||
Adjusted Net Income Attributable to Amedisys, Inc. per Diluted Share Reconciliation:
| For the Three-Month Periods Ended March 31, | ||||||
| 2025 | 2024 | |||||
| Net income attributable to Amedisys, Inc. common stockholders per diluted share | $ | 1.84 | $ | 0.44 | ||
| Add: | ||||||
| Certain items(1) | (0.59 | ) | 0.59 | |||
| Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share(4)(5) | $ | 1.25 | $ | 1.03 | ||
(1) The following details the certain items for the three-month periods ended March 31, 2025 and 2024:
Certain Items (in thousands):
| For the Three-Month Periods Ended March 31, | |||||||
| 2025 | 2024 | ||||||
| (Income) Expense | (Income) Expense | ||||||
| Certain Items Impacting General and Administrative Expenses: | |||||||
| Merger-related expenses | $ | 16,769 | $ | 20,667 | |||
| Certain Items Impacting Total Other Income (Expense): | |||||||
| Other (income) expense, net (includes $48,093 gain on equity method investment) | (48,672 | ) | (371 | ) | |||
| Total | $ | (31,903 | ) | $ | 20,296 | ||
| Net of tax | $ | (19,430 | ) | $ | 19,548 | ||
| Diluted EPS | $ | (0.59 | ) | $ | 0.59 | ||
(2) Adjusted EBITDA is defined as net income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items as described in footnote 1.
(3) Adjusted net income attributable to Amedisys, Inc. is defined as net income attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items as described in footnote 1.
(4) Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share is defined as diluted income per share calculated in accordance with GAAP excluding the earnings per share effect of certain items as described in footnote 1.
(5) Adjusted EBITDA, adjusted net income attributable to Amedisys, Inc. and adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share should not be considered as an alternative to, or more meaningful than, income before income taxes or other measures calculated in accordance with GAAP. These calculations may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate these non-GAAP financial measures in the same manner.
